Alcohol, Drugs and Addictive Behaviours
The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours.

Screening and brief intervention for alcohol problems in primary health care

 

BACKGROUND

There are many forms of excessive drinking that cause substantial risk or harm to the individual. They include high level drinking each day, repeated episodes of drinking to intoxication, drinking that is actually causing physical or mental harm, and drinking that has resulted in the person becoming dependent on alcohol. Excessive drinking causes illness and distress to the drinker and his or her family and friends. It is a major cause of breakdown in relationships, trauma, hospitalization, prolonged disability and early death. Alcohol-related problems represent an immense economic loss to many communities around the world. 

 

Screening for alcohol use: why AUDIT?

The AUDIT was developed as a simple method of screening for excessive drinking and to assist in brief assessment. It can help identify excessive drinking as the cause of the presenting illness. It provides a framework for intervention to help risky drinkers reduce or cease alcohol consumption and thereby avoid the harmful consequences of their drinking. The AUDIT also helps to identify alcohol dependence and some specific consequences of harmful drinking. Of utmost importance for screening is the fact that people who are not dependent on alcohol may stop or reduce their alcohol consumption with appropriate assistance and effort. The manual is particularly designed for health care practitioners and a range of health settings, but with suitable instructions it can be self-administered or used by non-health professionals. 

Screening for alcohol consumption among patients in primary care carries many potential benefits. It provides an opportunity to educate patients about low-risk consumption levels and the risks of excessive alcohol use. Information about the amount and frequency of alcohol consumption may inform the diagnosis of the patient's presenting condition, and it may alert clinicians to the need to advise patients whose alcohol consumption might adversely affect their use of medications and other aspects of their treatment. Screening also offers the opportunity for practitioners to take preventative measures that have proven effective in reducing alcohol-related risks. 

Development and validation of the AUDIT

The AUDIT was developed and evaluated over a period of two decades, and it has been found to provide an accurate measure of risk across gender, age and cultures. As the first screening test designed specifically for use in primary care settings, the AUDIT has the following advantages:

  • Cross-national standardization: the AUDIT was validated on primary health care patients in six countries. It is the only screening test specifically designed for international use;
  • Identifies hazardous and harmful alcohol use, as well as possible dependence;
  • Brief, rapid and flexible;
  • Designed for primary health care workers;
  • Consistent with ICD-10 definitions of alcohol dependence and harmful alcohol use;
  • Focuses on recent alcohol use.

BRIEF INTERVENTION

Brief interventions are those practices that aim to identify a real or potential alcohol problem and motivate an individual to do something about it. Brief interventions have become increasingly valuable in the management of individuals with alcohol-related problems. During the past 20 years, there have been numerous randomized trials of brief interventions in a variety of health care settings. Studies have been conducted in Australia, Bulgaria, Mexico, the United Kingdom, Norway, Sweden, the United States and many other countries. Results from these studies show that there is clear evidence that well-designed brief intervention strategies are effective, low-cost and easy to administer.

Because research has shown that brief interventions are low in cost and have proven to be effective across the spectrum of alcohol problems, health workers and policy-makers have increasingly focused on them as tools to fill the gap between the primary prevention efforts and more intensive treatment for persons with serious alcohol use disorders. It is worth noting that brief interventions are not designed to treat persons with alcohol dependence, which generally requires greater expertise and more intensive clinical management. However, they might serve well as as initial treatment for severely dependent patients seeking extended treatment.

Alongside with the companion publication on the AUDIT, WHO has also produced a manual to aid primary health care workers in administering brief interventions to persons whose alcohol consumption has become hazardous or harmful to their health. Together, these manuals describe a comprehensive approach to alcohol screening and brief intervention (SBI) that is designed to improve the health of the population and patient groups as well as individuals. 

 

Related activities:

The ASSIST project - Alcohol, Smoking and Substance Involvement Screening Test

 

 

Publications

This manual introduces the AUDIT, the Alcohol Use Disorders Identification Test, and describes how to use it to identify persons with hazardous and harmful...

Mapping climate change and health indicators

This review sheds light on how countries are measuring the health impacts of climate change. It examines the indicators countries are using in their vulnerability...

Elimination of human onchocerciasis: progress report, 2024–2025

Onchocerciasis, or river blindness, remains a major public health challenge despite decades of sustained efforts. More than 99% of population requiring...

Progress in eliminating onchocerciasis in the WHO Region of the Americas: Report from the Inter-American Conference on Onchocerciasis, 2024

Human onchocerciasis (river blindness) is caused by the parasitic worm Onchocerca volvulus, transmitted by Simulium black flies that breed in fast-flowing...

Access to medical products in the South-East Asia Region 2025

Access to Medical Products in the WHO South-East Asia Region 2025 is a biennial publication documenting progress and challenges in ensuring equitable access...

Report of the 4th Life Course Network meeting, 18-19 November 2024 - Extending healthy ageing across the life course: connecting healthy development and healthy ageing

World Health Organization (WHO)’s work on the life course – connecting optimal development and healthy ageing – aims to extend learning...

Reporting on the world’s biggest killers: a journalist’s guide to covering noncommunicable diseases

Reporting on the world’s biggest killers: a journalist’s guide to covering noncommunicable diseases, a new publication from WHO that is packed...

WHO Academy quality standards: leading lifelong learning for a healthier world

The WHO Academy serves as a transformative force in global health education, dedicated to empowering health professionals, policymakers, and public health...

WHO consolidated guidelines on tuberculosis: module 6: tuberculosis and comorbidities, 2nd ed.

Addressing TB comorbidities and risk factors is central to the World Health Organization (WHO) End TB Strategy. These guidelines consolidate the latest...

Third Regional Consultation on SEAHEARTS: Extended and Expanded Milestones 203025 September 2025 | 09:30- 11:30 ISTThe Third Regional Consultation on SEAHEARTS:...

WHO global report on trends in prevalence of tobacco use 2000–2024 and projections 2025–2030

This report presents WHO estimates of tobacco use prevalence among the population aged 15 years and older from 2000–2024, with trends projected to...

Eleventh Meeting of South-East Asia Region Polio Network and Capacity Building Workshop on Risk Assessment (Hybrid)

Meeting and Workshop Details: The four-day South-East Asia Region Polio Laboratory Network (SEAR PLN) meeting was hosted by the World Health Organization...

Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage

Despite the existence of proven interventions for preventing, diagnosing and treating postpartum haemorrhage (PPH), effective implementation of evidence-based...

Bleeding after birth: course on prevention, diagnosis and treatment of postpartum haemorrhage

The Bleeding after birth training course aims to translate standards into care. It incorporates the latest WHO recommendations related to PPH and includes...

Global programme to eliminate lymphatic filariasis: progress report, 2024

Lymphatic filariasis (LF) is a vector-borne, parasitic disease in humans that results in immense suffering among people affected. This neglected...

WHO Drug Information - Volume 39, No. 3

The Third issue of volume 39 for 2025 includes:Consultation Documents: Cefiderocol sulfate tosilate (cefiderocoli sulfas tosilatum) Cefiderocol powder...

The Work of WHO in the South-East Asia Region, Report of the Regional Director,
1 January–31 December 2024

This Annual Report of the Regional Director describes the work of the World Health Organization in the South-East Asia Region from 1 January to 31 December...

Land use planning: sectoral solutions for air pollution and health

Exposure to air pollution and its associated health impacts are affected by land use practices including their regulation and enforcement. Understanding...

Global guidance on monitoring public health and social measures policies during health emergencies, rev. ed., 2025.

This global guidance aims to facilitate systematic and harmonized data collection about, and monitoring of, public health and social measures (PHSM) policies...

Accelerating the development of priority formulations in childhood cancer: target product profiles for paediatric formulations of cyclophosphamide, etoposide, mercaptopurine, methotrexate, procarbazine, temozolomide

This document summarizes the proceedings and outcomes of a technical consultation designed to develop target product profiles for six priority childhood...

Analysis of antibacterial agents in clinical and preclinical development: overview and analysis 2025

The World Health Organization’s (WHO) “2025 Antibacterial agents in clinical and preclinical development: an overview and analysis” report...

Related resources

The ASSIST-linked brief intervention for hazardous and harmful substance use

This manual is a companion to ‘The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): manual for use in primary care’. The...

The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was developed for the World Health Organization (WHO) by an international group...

Self-help strategies for cutting down or stopping substance use (ASSIST)

Substance use problems can arise as a result of acute intoxication, regular use or dependence - and from the way in which substances are used. This guide...

Guidelines for identification and management of substance use and substance use disorders in pregnancy

These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which...

mhGAP Intervention Guide - Version 2.0

This is the second version (2016) of the mhGAP Intervention Guide (mhGAP-IG) for mental, neurological and substance use (MNS) disorders in non-specialist...

mhGAP Training Manuals - for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings, version 2.0

As part of the Mental Health Gap Action Programme, WHO has developed training manuals (Training of trainers and supervisors training manual and Training...

Involvement of nurses and midwives in screening and brief interventions

Psychoactive substance use can result in a wide range of health and social problems for individuals, their families and the wider community. Globally,...